List Biotherapeutics Break Ground on New Fishers Microbiome Manufacturing Facility
City of Fishers representatives joined List Biotherapeutics, Inc. (List Bio), List Labs, and Genome & Company executives to break ground on List Bio’s new $125 million, 110,000 square foot contract manufacturing facility on Tuesday. The facility, which spans 15 acres in the Fishers Life Science & Innovation Park, will be completed by the end of 2023.
List Bio parent company, Korean-based Genome & Company (KOSDAQ: 314130), invested in the firm’s sister company, List Labs, to expand its manufacturing capabilities to offer an end-to-end manufacturing solution from early-stage development to late-stage clinical trials and commercialization. The company plans to hire 210 employees in Fishers in the areas of biologics manufacturing and quality and regulatory compliance.
“Breaking ground on yet another headquarters at the Life Science & Innovation Park is a humbling moment,” said Fishers Mayor Scott Fadness. “Our vision to create a hub for biopharma and biotech is becoming a reality and we’re grateful that the teams at Genome and List Bio have entrusted Fishers to be their home, where they will impact lives all around the world.”
List Bio’s commitment to the City of Fishers is another example of how the community’s business, talent, and innovation climates are coming together to create an ideal landing spot for biotech and biopharma companies. The City of Fishers has had $750 million in investment from biotech and biopharma companies since 2020.
For more information about the Fishers Life Science & Innovation Park, visit fishersecondev.com.
Since its establishment in 2015, Genome & Company develops next waves of innovative drugs including anti-cancer microbiome therapeutics and novel target immune checkpoint inhibitors. Through continuing open innovations with global external collaborations and strategic investments, the company has expanded its microbiome pipeline into central nervous system disorders such as autisms and continues to pioneer the market in becoming a fully integrated global healthcare group capable of research, development, and manufacturing of first-in-class pharmaceutical modalities including microbiome. For more information, visit their website at http://www.genomecom.co.kr.
List Biological Laboratories, Inc, has over 40 years of experience with bacterial-derived products. Developing and manufacturing one of the first Live Biotherapeutic Products to enter into a clinical trial, List Labs offers microbiome-derived drug development experience second to none. The result is an impressive track record of successful collaborations with clients for cGMP manufacturing and a catalog of over 100 bacterial products used in medical research and vaccine development throughout the world. Headquartered in Campbell, CA, List Labs offers world-class expertise in drug product development including bacterial fermentation, protein purification, process development, analytical development, scale-up, and development of robust cGMP manufacturing processes for drug products used in clinical trials. For more information, go to their website, http://www.listlabs.com, or contact Gary Henderson, Director of Business Development at ghenderson@listlabs.com.
The City of Fishers is a suburb of Indianapolis, Indiana, located in Hamilton County and was named #1 Place to Live in the US by Money Magazine in 2017. Under the leadership of Mayor Scott Fadness, Fishers is known as a smart, vibrant, and entrepreneurial city through its neighborhood development, dedication to supporting high-growth companies, and innovative city processes. With a population of 91,832 (2017), Fishers is one of the fastest growing communities in Indiana and has received national accolades for entrepreneurship, livability, and safety